Following similar logic, pharmaceutical companies are also poised to profit from Obamacare with more individuals seeking preventative care and pharmaceutical treatments.
"Pharma ETFs have rewarded investors with handsome returns over the years, despite their somewhat volatile nature [see also 3 Simple All-ETF``Core""Portfolios]."